Filgotinib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Filgotinib" in English language version.

refsWebsite

Global rank English rank

6nih.gov

4^th place

4doi.org

2^nd place

4web.archive.org

1^st place

4clinicaltrials.gov

5,225^th place

4,062^nd place

4globenewswire.com

2,614^th place

1,549^th place

3gilead.com

low place

3europa.eu

68^th place

117^th place

3glpg.com

low place

2businesswire.com

615^th place

407^th place

2fiercebiotech.com

low place

8,828^th place

1medicines.org.uk

3,823^rd place

2,387^th place

1abbvie.com

low place

1acrabstracts.org

low place

1euroinvestor.com

low place

1yahoo.com

38^th place

40^th place

abbvie.com

news.abbvie.com

"AbbVie to Advance Once-Daily ABT-494 to Phase 3 in Rheumatoid Arthritis by Year-End". AbbVie (Press release). Archived from the original on 8 January 2018. Retrieved 9 January 2018.

acrabstracts.org

Florence N, Julie D, Van der Aa A, Tasset C, van't Klooster G (2014). "Phase 1 and Phase 2 Data Confirm That GLPG0634, a Selective JAK1 Inhibitor, Has a Low Potential for Drug-Drug Interactions". Meeting Abstracts. 2014 ACR/ARHP Annual Meeting. American College of Rheumatology. 1481.

businesswire.com

"European Commission Grants Marketing Authorization for Jyseleca (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis" (Press release). Gilead Sciences. 25 September 2020. Retrieved 4 October 2020 – via Business Wire.
"Jyseleca (Filgotinib) Approved in Japan for Rheumatoid Arthritis". Gilead Sciences. 25 September 2020. Retrieved 4 October 2020 – via Business Wire.

clinicaltrials.gov

Clinical trial number NCT01384422 for "Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis" at ClinicalTrials.gov
Clinical trial number NCT01888874 for "Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Patients (DARWIN1)" at ClinicalTrials.gov
Clinical trial number NCT02065700 for "Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Patients" at ClinicalTrials.gov
Clinical trial number NCT03201445 for "Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Ulcerative Colitis" at ClinicalTrials.gov

doi.org

Namour F, Diderichsen PM, Cox E, Vayssière B, Van der Aa A, Tasset C, et al. (August 2015). "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection". Clinical Pharmacokinetics. 54 (8): 859–74. doi:10.1007/s40262-015-0240-z. PMC 4513223. PMID 25681059.
Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, et al. (October 2013). "Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases". Journal of Immunology. 191 (7): 3568–77. doi:10.4049/jimmunol.1201348. PMID 24006460.
Westhovens R, Taylor PC, Alten R, Pavlova D, Enríquez-Sosa F, Mazur M, et al. (June 2017). "Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)". Annals of the Rheumatic Diseases. 76 (6): 998–1008. doi:10.1136/annrheumdis-2016-210104. PMID 27993829.
Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, et al. (July 2019). "Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial". JAMA. 322 (4): 315–325. doi:10.1001/jama.2019.9055. PMC 6652745. PMID 31334793.

euroinvestor.com

"Galapagos completes recruitment for Darwin 1 study with GLPG0634 (filgotinib) in RA" (Press release). Galapagos NV. Archived from the original on 26 February 2015. Retrieved 26 February 2015 – via GlobeNewswire.

europa.eu

ema.europa.eu

"Jyseleca EPAR". European Medicines Agency (EMA). 26 May 2020. Retrieved 4 October 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Jyseleca: Pending EC decision". European Medicines Agency (EMA). 23 July 2020. Archived from the original on 27 July 2020. Retrieved 27 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

ec.europa.eu

"Jyseleca Product information". Union Register of medicinal products. Retrieved 3 March 2023.

fiercebiotech.com

"FDA rejects Gilead's would-be blockbuster filgotinib over toxicity concerns". 19 August 2020.
"Galapagos, Gilead include high dose in PhIII RA trial after talk with FDA". FierceBiotech. Retrieved 8 January 2018.

gilead.com

"Pipeline". Gilead Sciences. 27 July 2020. Retrieved 27 July 2020.
"Gilead Submits Filgotinib New Drug Application to U.S. Food and Drug Administration Under Priority Review for Rheumatoid Arthritis Treatment". Gilead Sciences, Inc. (Press release). 19 December 2019. Retrieved 27 July 2020.
"Gilead and Galapagos Announce Positive European CHMP Opinion for Jyseleca (Filgotinib) for the Treatment of Adults With Moderate to Severe Rheumatoid Arthritis". Gilead Sciences, Inc. (Press release). 24 June 2020. Retrieved 27 July 2020.

globenewswire.com

"Galapagos' selective JAK1 inhibitor filgotinib meets key efficacy endpoints, shows ACR70 responses up to 39%, and maintains safety profile after 24 weeks of treatment in DARWIN 1 Phase 2B study" (Press release). Galapagos NV. 29 July 2015 – via GlobeNewswire.
"DARWIN 2 24-week monotherapy data in RA confirm previous results and support best-in-class potential for filgotinib" (Press release). Galapagos NV. 10 August 2015 – via GlobeNewswire.
"Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study" (Press release). Galapagos NV. 5 November 2017 – via GlobeNewswire.

ml-eu.globenewswire.com

"Gilead and Galapagos Announce Positive European CHMP Opinion for Jyseleca (Filgotinib) for the Treatment of Adults With Moderate to Severe Rheumatoid Arthritis" (Press release). 24 July 2020. Retrieved 27 July 2020.

glpg.com

"Galapagos' GLPG0634 shows excellent efficacy and safety in rheumatoid arthritis Phase II study" (PDF) (Press release). Retrieved 26 February 2015.^{[permanent dead link‍]}
"Galapagos reports that the last patient in DARWIN 1 has completed 12 weeks of treatment" (PDF) (Press release). Archived from the original (PDF) on 26 February 2015. Retrieved 26 February 2015.

reports.glpg.com

"Filgotinib program in RA - Galapagos Annual Report 2016". Galapagos. Retrieved 8 January 2018.

medicines.org.uk

"Jyseleca 100 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 1 October 2020. Retrieved 4 October 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Namour F, Diderichsen PM, Cox E, Vayssière B, Van der Aa A, Tasset C, et al. (August 2015). "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection". Clinical Pharmacokinetics. 54 (8): 859–74. doi:10.1007/s40262-015-0240-z. PMC 4513223. PMID 25681059.
Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, et al. (October 2013). "Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases". Journal of Immunology. 191 (7): 3568–77. doi:10.4049/jimmunol.1201348. PMID 24006460.
Westhovens R, Taylor PC, Alten R, Pavlova D, Enríquez-Sosa F, Mazur M, et al. (June 2017). "Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)". Annals of the Rheumatic Diseases. 76 (6): 998–1008. doi:10.1136/annrheumdis-2016-210104. PMID 27993829.
Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, et al. (July 2019). "Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial". JAMA. 322 (4): 315–325. doi:10.1001/jama.2019.9055. PMC 6652745. PMID 31334793.

ncbi.nlm.nih.gov

Namour F, Diderichsen PM, Cox E, Vayssière B, Van der Aa A, Tasset C, et al. (August 2015). "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection". Clinical Pharmacokinetics. 54 (8): 859–74. doi:10.1007/s40262-015-0240-z. PMC 4513223. PMID 25681059.
Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, et al. (July 2019). "Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial". JAMA. 322 (4): 315–325. doi:10.1001/jama.2019.9055. PMC 6652745. PMID 31334793.

web.archive.org

"AbbVie to Advance Once-Daily ABT-494 to Phase 3 in Rheumatoid Arthritis by Year-End". AbbVie (Press release). Archived from the original on 8 January 2018. Retrieved 9 January 2018.
"Jyseleca: Pending EC decision". European Medicines Agency (EMA). 23 July 2020. Archived from the original on 27 July 2020. Retrieved 27 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Galapagos reports that the last patient in DARWIN 1 has completed 12 weeks of treatment" (PDF) (Press release). Archived from the original (PDF) on 26 February 2015. Retrieved 26 February 2015.
"Galapagos completes recruitment for Darwin 1 study with GLPG0634 (filgotinib) in RA" (Press release). Galapagos NV. Archived from the original on 26 February 2015. Retrieved 26 February 2015 – via GlobeNewswire.

yahoo.com

finance.yahoo.com

"Galapagos completes recruitment for Darwin 2 monotherapy study with GLPG0634 (filgotinib) in RA" (Press release). Galapagos NV. 24 November 2014. Retrieved 26 February 2015 – via GlobeNewswire.